Life Sciences

Pharma’s U.S. reputation is bad—and Trump may be to blame: survey

July 21, 2017

The pharma industry’s reputation among patient groups in the U.S. has sunk to a recent low, and some are pointing to the country’s leader as the reason. Only 29% of groups recently surveyed by research firm PatientView believe pharma has an “excellent” or “good” corporate..

Sanofi offers Ablynx billions of biobucks for nanobody partnership

July 20, 2017

Belgian biotech Ablynx just signed a potentially lucrative new deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front. The new deal is a fillip for Ablynx after AbbVie declined to take up rights to..

Reuters: U.S. Cardinal Health puts $1.5 billion China business on block

July 20, 2017

U.S. drug distributor Cardinal Health has put its China business up for sale, drawing keen interest from state-backed Chinese pharmaceutical firms in a deal that may be worth up to $1.5 billion, sources familiar with the matter said. Shanghai Pharmaceutical Holding Co Ltd, China Resources..

Novartis CEO says shopping for bolt-ons is tough.

July 20, 2017

Amid a noted slowdown in biopharma M&A, fresh comments from Novartis CEO Joe Jimenez signal the challenges facing the industry’s dealmakers. Namely, too-high biotech valuations have forced the Swiss drugmaker’s M&A scouts to eye earlier-stage assets. Jimenez said Tuesday that Novartis is “still very focused..

GSK revamp to cost U.K. hundreds of manufacturing jobs

July 19, 2017

GlaxoSmithKline is looking to unload some marginal businesses and make other cuts that it says will cost about 320 manufacturing jobs in its home country over the next three years. In addition, the company is canceling plans to build a new biologics plant there that..

EU watchdog asks if drugmakers influence EMA decisions

July 19, 2017

The European Union is investigating whether presubmission meetings with the EMA enable drug companies to influence marketing authorization approval decisions. Officials at the EMA must now allay concerns their meetings with sponsors introduce a source of bias into their decision-making. Drug companies meet with the..

Takeda relocates hundreds of R&D, vaccine jobs and cuts 480 in sales

July 18, 2017

Hundreds of Takeda employees in R&D and vaccines have been asked to relocate from suburban Chicago to the Boston area as part of a two-year effort to position its U.S. jobs in the vibrant scientific hub, according to a new report. As reported by Modern..

Shire pens bispecific hemophilia R&D deal with Novimmune

July 18, 2017

As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies. Shire and newly-acquired Baxalta have long had medications on the market for the condition, but these are under threat from Roche and its experimental hemophilia A med..

SynteractHCR taps industry veteran Steve Powell as new CEO

July 18, 2017

Having served as senior-level executive at such clinical service providers as Exco InTouch and PRA Health Sciences, Steve Powell has taken the helm at SynteractHCR, succeeding Wendel Barr, the CRO’s CEO for the past six years. “[A] respected leader who has built an impressive track..

Ex-Novo executive signs at Radius

July 18, 2017

With Amgen’s competing bone drug now sidelined, Radius has a big opportunity ahead with its Tymlos launch. And the company is staffing up accordingly. Monday, the Massachusetts biotech said it had brought on Jesper Høiland, former president of Novo Nordisk’s U.S. business, as its new..